Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Change in Accured Expenses (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Change in Accured Expenses for 6 consecutive years, with $48000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 98.95% to $48000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $142000.0, a 96.95% decrease, with the full-year FY2025 number at $142000.0, down 96.95% from a year prior.
  • Change in Accured Expenses was $48000.0 for Q4 2025 at PROCEPT BioRobotics, up from -$1.5 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $5.5 million in Q2 2024 to a low of -$6.0 million in Q1 2023.
  • A 5-year average of $686250.0 and a median of $149000.0 in 2022 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: surged 14125.0% in 2024, then plummeted 4414.71% in 2025.
  • PROCEPT BioRobotics' Change in Accured Expenses stood at $1.1 million in 2021, then soared by 180.57% to $3.2 million in 2022, then crashed by 98.99% to $32000.0 in 2023, then soared by 14125.0% to $4.6 million in 2024, then tumbled by 98.95% to $48000.0 in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Change in Accured Expenses are $48000.0 (Q4 2025), -$1.5 million (Q3 2025), and $1.5 million (Q2 2025).